NOTHING IS EVERYTHING.

Nothing less than the opportunity to reach for their treatment goals

For your patients, that’s everything.

Durable, Rapid & Clear

In Ps, most patients achieved co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16, including response 4 weeks after 1st dose. Most patients who achieved PASI 90 at Week 16 maintained it at Week 52. PASI 100 was achieved by many patients at Week 16 and by a majority at Week 52.1-3

VIEW Ps EFFICACY

Powerful Joint Symptom Relief

In PsA, a majority of patients achieved the primary endpoint of ACR20 at Week 24, experiencing improvement in joint symptoms including patient-reported pain data.1

VIEW PsA EFFICACY

4 Doses a Year

Reliable quarterly dosing after 2 initiation doses at
Weeks 0 and 4 (150 mg/injection) for Ps and PsA.1

VIEW DOSING

PASI 90=≥90% improvement in Psoriasis Area and Severity Index; PASI 100=100% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician’s Global Assessment rating of clear or almost clear.

Skyrizi single-dose pen.


THE ONLY 4-DOSE-A-YEAR SYSTEMIC FOR PSORIASIS AND FOR PSORIATIC ARTHRITIS THAT OFFERS A SINGLE-DOSE PEN1

FIND OUT MORE
SKYRIZI® is the #1 prescribed systemic by dermatologists for patients with psoriatic disease.

#1 PRESCRIPTION ANALYSIS CALCULATED BY COMBINED PRESCRIPTION DATA ACROSS Ps AND PsA

 

For patients with psoriatic disease, defined as those with plaque psoriasis or psoriatic arthritis.
Source of data: Integrated Symphony Health as of 9/2023.4 The term branded systemic is defined as systemic drugs that are sold by a specific name or trademark and protected by patent. This analysis did not include over-the-counter (OTC) medications.

99%

PREFERRED* NATIONAL COMMERCIAL FORMULARY COVERAGE UNDER THE PHARMACY BENEFIT AS OF JANUARY 2025 IN Ps AND PsA5†

VIEW ACCESS

*SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

THE ONLY Ps TREATMENT WITH SUPERIORITY DATA VS 4 AGENTS, INCLUDING AN ORAL2,6-8

Man in a blue swimsuit jumps into a lake

COSENTYX® (secukinumab)7§

SEE DATA
Woman in a blue dress raises her hands in celebration towards her friends

STELARA®
(ustekinumab)1,2∥

SEE DATA
Woman in blue top overlooking a lake

HUMIRA®
(adalimumab)8

SEE DATA

OTEZLA®
(apremilast)6‡

SEE DATA
Skyrizi® (risankizumab-rzaa) Logo.

SKYRIZI HEAD-TO-HEAD DATA VS 3 AGENTS IN DIFFERENT BIOLOGIC CLASSES

Man in a blue swimsuit jumps into a lake

COSENTYX® (secukinumab)6‡

SEE DATA
Woman in a blue dress raises her hands in celebration towards her friends

STELARA®
(ustekinumab)1,2§

SEE DATA
Woman in blue top overlooking a lake

HUMIRA®
(adalimumab)7

SEE DATA

HUMIRA®
(adalimumab)7

SEE DATA
Click to see HUMIRA® (adalimumab)

Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See

Full Prescribing Information

‡Evaluated in patients with moderate plaque psoriasis eligible for systemic therapy.

§SOURCING: In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab are not publicly available.9

∥ACTIVE COMPARATOR: The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.

Products and their designs are trademarks of their respective owners.

At week 161,2: 75% of Skyrizi patients (n=220/294) achieved pasi 90 in the UltIMMa-2 study vs 2% of placebo patients (n=2/98);

84% of SKYRIZI patients achieved sPGA 0/1 vs 5% of placebo patients

UltlMMa-1 results at Week 16
PASI 90: SKYRIZI 75% (n=304), placebo 5% (n=102)
sPGA 0/1: SKYRIZI 88% (n=304), placebo 8% (n=102)

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

p<0.0001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS
SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA
Man folding arms.
Woman in blue swimsuit Woman in blue swimsuit Woman in blue swimsuit

WATCH VIDEO:

SEE THE POSSIBILITIES WITH SKYRIZI
Woman folding arms.

At week 521,2: 81% of Skyrizi patients (n=237/294) achieved pasi 90 in the UltIMMa-2 study; placebo did not continue beyond Week 16

UltlMMa-1 results at Week 52
PASI 90: SKYRIZI 82% (n=249/304), placebo n/a

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

p<0.0001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS
SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA

Explore
Long-term data

SKYRIZI has long-term efficacy data in Ps
(~6 years) and PsA (~3 years), and long-term safety data (~9 years in Ps, 4 years in PsA)10-13

Ps EFFICACY
PsA EFFICACY
SAFETY
Woman folding arms.

4 doses
per year1

3-month dosing after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)

VIEW DOSING SCHEDULE
COMPLETE Pro.

FOR BIOCOORDINATORS & OFFICE STAFF

Complete Pro is a flexible and easy-to-use portal designed to streamline and manage the prescription process so patients can start and stay on track with their prescribed treatment.

LEARN MORE ABOUT COMPLETE PRO
Man standing.

PREFERRED COVERAGE FOR 99% OF COMMERCIAL Ps AND PsA PAYERS' LIVES5#

National commercial formulary coverage under the pharmacy benefit as of January 2025

 

 

Skyrizi® Complete Logo.

Eligible patients may be able to access their SKYRIZI at no charge until their insurance plan covers SKYRIZI or up to 2 years, whichever occurs earlier.**

VIEW SKYRIZI COMPLETE

SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.

#Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

**Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.